Health Economics›Ovarian cancer›Relapsed or recurrent disease platinum-sensitive

Relapsed or recurrent disease platinum-sensitive

Ovarian cancer · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Olaparib monotherapy Variant #01	HRD	R 59 224	28d	~13.4 mo	~40.9 mo	~15	~R 888 360 PFS proxy · indirect	8
Pegylated liposomal doxorubicin monotherapy Variant #01	HRD	R 15 300	28d	~3.9 mo	~13.5 mo	~5	~R 76 500 PFS proxy · indirect	18
Gemcitabine monotherapy Variant #20	HRD	R 14 213	56d	~3.3 mo	~15.0 mo	~2	~R 28 426 PFS proxy · indirect	4
Topotecan monotherapy Variant #01	HRD	R 11 563	21d	~4.0 mo	~13.4 mo	~6	~R 69 379 PFS proxy · indirect	9
Paclitaxel monotherapy Variant #46	HRD	R 2 220	28d	~4.4 mo	~14.0 mo	~5	~R 11 098 PFS proxy · indirect	18
Carboplatin monotherapy Variant #01	HRD	R 1 231	21d	5.8 mo	21.0 mo	9	R 11 076 PFS proxy	2

6 of 6 regimens shown